On June 4, Sanofi rose 4.59% in regular trading, trading at $44.56/share, with trading volume of $27.25 million. The rally was driven by the announcement that its first-in-class drug Venglustat received FDA acceptance and priority review designation for the treatment of Type 3 Gaucher disease.

Specifically, if approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3. The FDA has set a target action date of November 25. The acceptance was primarily based on positive results from the Phase 3 LEAP2MONO study, in which Venglustat met both primary endpoints and three out of four key secondary endpoints. Gaucher disease causes abnormal accumulation of sugar-and-fat molecules in the spleen, liver, bone marrow, and lungs, potentially leading to neurological and cognitive challenges.

Additionally, Sanofi recently advanced the clinical application of a first-in-class JAK/ROCK dual-target inhibitor, further expanding its innovative pipeline in hematology and transplantation. Within the Pharmacy sector, broader strength was observed with Eli Lilly up 3.89%, Merck up 4.49%, Novo-Nordisk up 4.56%, and Pfizer up 2.15%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)